

FW: Presentations from Munich Benzene Symposium

From:

"Cushman, Janette (JCushman)" <jcushman@chevron.com>

To:

"Jackson, Lucinda (LUAJ)" <lucindajackson@chevron.com>

Cc:

"Satin, Ken (KSAT)" <ksat@chevron.com>, "Stine, Eric (ESTine)" <estine@chevron.com>

Date:

Thu, 01 Oct 2009 17:48:53 +0100

Attachments:

WONG Munich presentation 2009-09-08.pdf (375.6 kB)

Here is the presentation on the benzene case control study that was presented in Munich. As you can see, it is a very technical presentation that is being reviewed by Eric Stine and Ken Satin.

- The first few slides talk about the design of the study.
- Slides 26 & 27 have the odds ratios (OR) for the acute myeloid leukemia (AML), summary of the results on slides 29 & 30
- Slide 47 has a summary of the OR for follicular lymphoma (FL – 7.00) (which falls into the broad category of non-Hodgkin lymphoid neoplasms - NHLN), summary of the results on slide 48.
- Limitations of the study are listed on slide 49 and conclusions on slide 50.

Regards,
Jan

Janette R. Cushman

Manager, Toxicology & Health Risk Assessment
Chevron Energy Technology Company
1450 Marina Way South
Richmond, CA 94804
1-510-242-9349

From: Stine, Eric (ESTine)

Sent: Tuesday, September 29, 2009 9:48 AM

To: Cushman, Janette (JCushman)

Subject: FW: Presentations from Munich Benzene Symposium

Jan,

As you requested, Otto Wong's presentation is the first one attached, above. Richard Iron's presentation is the second presentation; also interesting, dealing with disease progression and MDS.

Eric

From: Howard Feldman [mailto:Feldman@api.org]

Sent: Friday, September 11, 2009 6:04 AM

To: BHRC Communications Committee; BenzConsort-TC@listserve.api.org; BenzConsort-OC@listserve.api.org

Cc: Kimberly Wise

Subject: Presentations from Munich Benzene Symposium

The Munich Benzene Symposium has now been completed. Subsequently, we have now solicited and received electronic versions of the presentations from several of the presenters.

- Thus far we have received presentations from Drs Otto Wong, Richard Irons, and Sherilyn Gross, which are attached.
- As additional presentations are received, we will forward them to the group.

Reminder that the next call of the BHRC Oversight Committee will be September 24 starting at 4 PM.

Howard J. Feldman

Director

Regulatory & Scientific Affairs

1220 L Street, NW

Washington, DC 20005-4070

USA

Telephone 202-682-8340

Fax 202-682-8270

E-mail feldman@api.org

